INTRODUCTION
The early literature on urogastrone contains several allusions to its ability to cause tissue proliferation as well as to inhibit acid secretion (Sandweiss, 1943) , but because the latter property lent itself to clear definition the purification and characterization of urogastrone was as an inhibitor of gastric acid secretion (Gregory, 1975) .
Comparison of the structure of urogastrone derived from human urine with the growth factor from the mouse submaxillary gland (Gregory, 1975; Savage, Inagami & Cohen, 1972) immediately indicated that they were most probably equivalent molecules from the different species. Subsequent studies have reinforced this belief and as both names, urogastrone and epidermal growth factor, are well-established in the literature it is justified to refer to U R O -EG F as the functional agent. Although it has been found in many secretions, and presumably has a function in the many tissues with receptors for U R O -EG F, the physiological role of U R O -E G F has not been defined. The rapidly expanding literature on U R O -EG F is dominated by studies on in vitro cell systems, which are exploring the mechanisms of action of the growth factor, but these need to be seen in relation to the concentrations found in vivo and the biological effects seen at physiological levels. The objective here, therefore, is to present in summary some of the relevant physiological data.
SOURCES AND CONCENTRATIONS OF URO-EGF IN MAN
Human U R O -EG F was readily immunogenic in rabbits and mice, and antisera could be selected with high specificity for the human molecule, e.g. where cross reaction with the mouse molecule with 70% homology was less than 1 in 10000.
These antisera have been used in immunofluorescence and immunoperoxidase localization studies, which showed strongly positive staining in human submandibular glands and Brunner's glands (Elder, Williams, Lacey & Gregory, 1978; Heitz et al. 1978) . In particular, the heavy staining of the duct cells in the latter gland in the duct lumen suggested an exocrine secretion. No other tissue gave definable positive results.
The specific antibodies were used also to provide an accurate radioimmunoassay, enabling fluid concentrations to be readily measured. Urine levels of U R O -E G F vary widely in the normal population (Gregory, Holmes & Wiltshire, 1977) and we have not found any significant variation in daily output in relation to body weight in a number of disease states. Thus patients with duodenal ulcer, Sjorgren's Syndrome or psoriasis did not show abnormal excretion of growth factor, nor did we find altered amounts in patients with different types of malignant growth. Raised levels have been reported in a number of patients with tumours when expressed in relation to the daily creatinine output (Uchihashi et al. 1983 ), whereas we related output to body weight. However, it is probable that urine output will not show small fluctuations in body content that may be physiologically important.
T he amounts of U R O -EG F in serum were also measured together with a number of secretions, saliva, gastric juice, etc. (Gregory, Walsh & Hopkins, 1979) , and it was clear that many secretions had concentrations far in excess of that found in serum. Furthermore, whilst the U R O -EG F in saliva and gastric juice had the same size and biological activity as the characterized peptide, that in serum had predominantly a much higher molecular size and lower potency. This was not due to a simple association with serum proteins, but treatment with the highly specific proteolytic enzyme trypsin gave rise to the smaller biologically active agent. Thus the blood contains U R O -EG F in precursor form, perhaps to be available on demand at some point in the body. When pure submandibular and parotid salivas were collected they had similar amounts of U R O -EG F present in both resting and stimulated secretions. Immunohistochemical studies had shown submandibular but not parotid cells to be rich in growth factor and, presumably, therefore, the parotid secretion was supplied from the general circulation. As the total immunoactivity in serum is rarely greater than 1 ng ml-1 and in saliva > lOngml-1 then some concentration must occur. The amounts in milk, urine and prostatic fluid can reach > 100 ng ml-1 . Once again no evidence of synthesis was observed in mammary tissue yet large amounts appeared in milk; presumably it is actively transported from serum. Normal mouse mammary epithelial cells do have functional receptors (Taketani & Oka, 1983) . Whereas breast tissue is oestrogen-responsive the prostate gland is androgen-responsive, and secretions from the latter do have very high concentrations of U R O -EG F. The mean concentration in human prostatic fluid of 280 ng ml-1 was the highest observed, apart from precolostrum, and it was predominantly the normal growth factor as charac terized from urine and accounted for the entire content of U R O -E G F in seminal fluid (Gregory et al. 1985) . Because of the observation that benign prostatic hypertrophy was uncommon in certain groups, e.g. native Chinese and Japanese, it is possible that it may be related to diet. As production of U R O -E G F from the duodenum may be influenced by diet, measurements were also made of concen trations in BPH patients to see if any relationship was apparent. In fact the amounts of U R O -E G F in prostatic fluid from BPH patients was approximately half that found in normal controls. No evidence of synthesis within prostatic tissue could be observed, implying that the growth factor in the secretions was a transported phenomenon, but the physiological relevance of reduced amounts in BPH was not clear.
In summary, therefore, two sites of origin are proposed in the human with low levels in serum but many tissues are exposed to U R O -EG F at concentrations > 1 0 0 n g m l-1 . Also many cells have specific receptors for the growth factor to promote activities, which may be divided arbitrarily into short-and long-term events.
RAPID ACTIONS 1
Human urogastrone was isolated using inhibition of gastric acid secretion as bioassay and the potency was clearly established in dogs in particular. U R O -E G F will inhibit secretion stimulated by histamine, pentagastrin or cholinergic stimu lation at doses of 0-l-l-0|Ugkg-1 . The effect is very rapid, in that 15min after parenteral administration to dogs with Heidenhain pouches the secretion from the pouches has stopped completely (Gregory, Bower & Willshire, 1977) . This may be entirely consistent in speed with the observed in vitro effect of U R O -E G F in inducing rapid phosphorylation at cell membranes upon binding to receptors. Clearance from blood of the injected factor is also very rapid, and following intravenous administration it is no longer detectable in blood by radioimmunoassay at 5m in. Also this clearance is reflected by rapid transfer into the urine in dogs, which reached completion by ~20 min, although this represents less than 10 % of the intravenous dose (Elder, Kiff & Gregory, 1978) . Other secretions such as pancreatic, biliary and salivary were not inhibited by similar doses of U R O -E G F. In other species gastric secretion was invariably inhibited, although with different potency; the rat was much less sensitive, but the human was more sensitive. If gastric secretion was evoked by histamine, pentagastrin, insulin, or the autonomous drive of gastrin in patients with Zollinger Ellison syndrome, or indeed by the basal tone of duodenal ulcer patients, inhibition occurred at ~0-25 fig kg" 1 (Koffman e ta l. 1982) .
Inhibition of acid secretion could be demonstrated using isolated mucosal preparations, indicating that the U RO -EG F was acting in the stomach and that inhibition was not a consequence of some distant phenomenon, although it was not due to direct action at either histamine 1 or 2 receptor (Gregory et al. 1977 ).
However, it has been shown to act directly at the parietal cell in a highly purified cell preparation. It has been shown (Chen, Amirian & Soli, 1984) that mouse U R O -E G F at 10-7 to 10-9 m blocked the histamine-stimulated amino pyrene uptake in these cells but did not have an effect upon post-membrane receptor stages. The direct effect of gastrin or cholinergic stimuli on these cells was not blocked. Thus inhibition of acid secretion in vivo is reflected as a specific in vitro action in isolated cells.
RAPID ACTIONS 2
The inhibition of gastric secretion is a rapid observable effect of U R O -E G F on parietal cells, but other cells are affected equally rapidly by becoming unresponsive to insult. Guinea pigs treated with reserpine over a short time developed gastric erosions; a concomitant infusion of U R O -EG F completely abolished this effect (Gregory-ei al. 1977 ). This cytoprotective effect was also demonstrated in rats and cats against gastric ulceration produced by acid and aspirin. The time scale of the experiment was 3 h and during that period U R O -EG F at doses below that necessary to inhibit acid secretion (0-25 jiigkg-1 h-1 in cats) prevented the formation of erosions (Konturek et al. 1981a ). This was achievable even though mucosal prostaglandin synthesis was much reduced by the aspirin, whereas the aspirinassociated decrease in mucosal DNA synthesis was prevented by U R O -E G F. Infusion of the growth factor into the lumen of the stomach at somewhat higher doses (1, 10 and 100 figkg~1 h-1 ) also gave a protective effect (Kontureket a l. 19816), and the amounts contained in salivary and duodenal secretions suggested a physiological role in the maintenance of gut integrity.
Whatever process is involved in cytoprotection it clearly is not dependent upon the full mitogenic response, which takes several hours in vitro, but rather on the very early membrane events, which occur immediately upon exposure of the cell to URO-E G F .
LONG-TERM ACTIONS
The consequence of treatment with U RO -EG F are to induce mitogenesis and in some cases differentiation, the indication being that it will enhance whatever function particular cells are programmed to perform. This has been shown in neonatal gut using the mouse peptide (Malo & Menard, 1982) , whereby some brush border enzymes are enhanced by single treatments whereas several applications are necessary for a mitogenic response. The longer-term actions can be explored by healing of wounds rather than preventing their formation as in cytoprotective studies. Relatively slowly healing duodenal ulcers can be produced in rats using acetic acid and the healing process can be accelerated by parenteral treatment with human U R O -EG F at 5 ¡M g kg-1 once daily (Gregory et al. 1977) . Impressive data on the effects that U R O -EG F can have on the gastrointestinal tract have been obtained from experiments with rats maintained on total parenteral nutrition (Goodlad et al. 1985) . Under these conditions crypt cell production rate (CCPR) fell to ~20% of orally fed controls, as determined by counting the cells arrested in metaphase following vincrystine treatment. U R O -EG F added to the parenteral food at 60;Ugkg_1 day-1 prevented the fall in CCPR and also restored the production rate in animals allowed to settle at the 20 % level. Thus the peptide alone will stimulate cell production along the length of the gastrointestinal tract. Given intragastrically at a higher dose (1-5 mg rat-1 day-1 ), it failed to have any effect in an intact gut in contrast to those reported in the presence of damaging agents such as aspirin or cysteamine. The latter agent will produce chronic duodenal ulcers in rats, which largely remain unhealed at SO days. Application of U R O -EG F continuously in the drinking water at 30 fig kg" 1 day-1 caused a significant increase in healing: 13 out of 29 compared to a control value of 2 out of a total of 28 animals (Olsen, Poulsen, Therkelsen & Nexo, 1985) . This was comparable to the healing rate produced by an antisecretory agent, cimetidine, at 500 mg kg-1 day-1 and the two agents together produced a greater effect: 19 out of 28 animals were healed. The test system is complex and time-consuming but these results support the view that U R O -E G F that is normally in secretions may have a role in the maintenance and repair of gut epithelium.
The implications are that U R O -EG F has effects in the gastrointestinal tract at doses below those influencing acid secretion and are most probably due to the mitogenic effects that were apparent in cell systems in vitro at similar concentrations.
Further confirmation of beneficial effects upon damaged tissue was provided by studies in rats in which small steel-mesh cylinders were placed in groups of four, subcutaneously, into rats (Hunt et al. 1985) . Test samples were placed in the cylinders and 14 days later the uptake of tissue and the hydroxyproline content of the cylinders were noted. Injections of 0-25 jug U R O -EG F into the cylinders produced a significant increase in wet and dry weights, and in hydroxyproline in the test cylinders. These observations were relevant to the tissue proliferation occurring in the healing of wounds. Whilst these studies did show that, in vivo, beneficial effects are seen with administration of U R O -EG F in the 'physiological' range, they do not necessarily define a physiological role. As mentioned earlier, U R O -E G F has clear effects upon the gut of neonatal mice, but there were also effects in utero\ administration of mouse U R O -EG F in utero to rabbits or sheep caused maturation of pulmonary epithelium and increased the weight of several organs: thyroid, liver, kidney, adrenals. A further study of urine output in newborn human infants was carried out on normal and premature infants. When expressed as the ratio to creatinine output, U RO -EG F rose steadily following birth from well below adult levels and appeared to be related to time of conception rather than time of delivery. There was no apparent inflexion enabling conclusions to be drawn about whether U R O -E G F plays a role in the maturation of gut or epidermis in the newborn (Evans, Rutter & Gregory, unpublished data).
SYNTHETIC URO-EGF
The natural molecule has good stability not only under extremes of solution pH conditions but also against mammalian enzymes such as pepsin and trypsin. As mentioned above, the biologically active peptide can be derived from a blood-borne precursor by tryptic-like action. Thus a synthetic gene prepared by G. D . Searle in a collaboration with IC I contained part of the Escherichia coli trpE gene linked via the gene coding for two lysine residues to the gene coding for human U R O -E G F (Smith et al. 1982) . The expressed protein from E. coli was partially purified, treated with trypsin and then purified by ion-exchange and gel chromatography to give a product indistiguishable from natural U R O -EG F. The physical data for both were the same and biologically the potency was indistinguishable, as both mitogen and inhibitor of gastric secretion.
It has been known for some time that mouse and human U R O -E G F have the same action in inducing eye opening in neonatal mice, which is a function of increased keratinization of the epidermis. Recently, the transforming growth factor, TGFar, has been synthesized by Genentech and its activity compared precisely with synthetic human and natural mouse U R O -EG F (Smith et al. 1985) . Dose-response curves with doses of 0-25-4-0 jUg-1 kg-1 day-1 show that all three have precisely the same potency in inducing this biological effect. Previously it had been noted that the human material lacking the C-terminal five amino acids and the similar mouse molecule both retained full secretory activity but reduced mitogenic potency. Surprisingly, therefore, the TGFar, which lacks this C-terminal sequence naturally, is fully active in the in vivo system. In addition to the studies described above conducted with human U R O -E G F, many others conducted with the mouse peptide confirm the useful mitogenic effects upon damaged tissues and support the hypothesis that its role may be that of wound hormone available on demand from a blood-borne reservoir. The ready availability of these peptides by biosynthesis should enable more detailed experiments to be carried out in the immediate future to clarify further the physiological relevance.
